Eric Auger recently was the Day 1 keynote speaker at the Northwind’s 11th Annual Life Sciences Invitational Forum held at Langdon Hall, Cambridge Ontario. An invitation only event, the forum brings together senior government policy-makers, senior life-sciences industry decision-makers, and patient advocates for open and honest dialogue regarding the challenging economic and political issues facing the Canadian health care system and life-sciences industry. The focus of this year’s forum was “Health & Life Sciences 2025 – Canada’s Evolving Landscape”.
Eric’s keynote detailed the launch of LUXTURNATM, the first gene therapy to be commercialized in the US market, and outlined the key challenges of balancing commercial viability and patient accessibility in commercializing the wave of emerging cell and gene therapies anticipated to come. The address highlighted the shared responsibility among industry, health care providers, payers, and government, to address barriers to patient access, as well as barriers to commercial models that will allow this emerging sector to deliver on its enormous potential to advance patient care and change lives. The discussion was moderated by Peter Brenders, General Manager, Canada, Sanofi Genzyme.